Municipal Treatment and Prevention Institution, City Hospital #33

Nizhny Novgorod

0 studies enrolling now · 2 studies all time

What they study most

Multiple Sclerosis, Relapsing-Remitting

Studies at this site

• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed